- Conditions
- Adenocarcinoma
- Interventions
- PEGPH20, Gemcitabine, Nab-paclitaxel
- Drug
- Lead sponsor
- Andrew Ko
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 697–720
of 1,628
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bladder Cancer
- Interventions
- gemcitabine hydrochloride, irinotecan hydrochloride
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Neoplasm
- Interventions
- PTK787/ZK222584
- Drug
- Lead sponsor
- Pancreatic Cancer Research Team
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Beverly Hills, California + 4 more
- Conditions
- Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, Leiomyosarcoma, Liposarcoma, Angiosarcoma, Synovial Sarcoma, Rhabdomyosarcoma, Spindle Cell Sarcoma, High Grade Sarcoma, Bone Sarcoma, Osteosarcoma, Ewing Sarcoma of Bone
- Interventions
- Gemcitabine, 9-ING-41, Docetaxel
- Drug
- Lead sponsor
- Brown University
- Other
- Eligibility
- 10 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 2
- States / cities
- Providence, Rhode Island
- Conditions
- Lung Cancer
- Interventions
- carboplatin, gemcitabine hydrochloride, paclitaxel
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001
- U.S. locations
- 57
- States / cities
- Loma Linda, California • Pomona, California • New London, Connecticut + 46 more
- Conditions
- Bladder Cancer
- Interventions
- Gemcitabine, Carboplatin, Sorafenib
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Metastatic Colorectal Adenocarcinoma
- Interventions
- Gemcitabine, Docetaxel, Filgrastim or Pegfilgrastim
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Bethesda, Maryland
- Conditions
- Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
- Interventions
- Gemcitabine Hydrochloride, Hydrocortisone/Placebo, Vismodegib
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 21 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 25
- States / cities
- Beverly Hills, California • Duarte, California • Los Angeles, California + 19 more
- Conditions
- Lymphoma, Solid Neoplasm
- Interventions
- Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Ribociclib
- Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Pancreatic Cancer
- Interventions
- erlotinib hydrochloride, gemcitabine hydrochloride, therapeutic conventional surgery
- Drug · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 23
- States / cities
- La Jolla, California • Los Angeles, California • Orange, California + 17 more
- Conditions
- Non-Muscle Invasive Bladder Cancer (NMIBC)
- Interventions
- Bacillus Calmette-Guérin (BCG), Gemcitabine
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 8
- States / cities
- Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
- Conditions
- Cervical Cancer
- Interventions
- gemcitabine hydrochloride
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Los Angeles, California • Los Gatos, California + 31 more
- Conditions
- Pancreatic Neoplasms
- Interventions
- Ascorbate, Gemcitabine, Radiation therapy
- Drug · Radiation
- Lead sponsor
- Joseph J. Cullen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- carboplatin, docetaxel, gemcitabine hydrochloride
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Urothelial Cancer
- Interventions
- Gemcitabine, Cisplatin, Sunitinib
- Drug
- Lead sponsor
- US Oncology Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 48
- States / cities
- Tucson, Arizona • Miami, Florida • New Port Richey, Florida + 42 more
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
- Interventions
- Mavrostobart (PT199), Tislelizumab, Gemcitabine + nab-Paclitaxel, Docetaxel, Pemetrexed, Gemcitabine, Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed
- Drug
- Lead sponsor
- Phanes Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 6
- States / cities
- Huntersville, North Carolina • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more
- Conditions
- Pancreas Adenocarcinoma
- Interventions
- NovoTTF-200T, Gemcitabine, nab paclitaxel
- Device · Drug
- Lead sponsor
- NovoCure Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 571 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 66 more
- Conditions
- Pancreatic Cancer
- Interventions
- trastuzumab, gemcitabine hydrochloride
- Biological · Drug
- Lead sponsor
- Brown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 12
- States / cities
- Chicago, Illinois • Boston, Massachusetts • New Brunswick, New Jersey + 5 more
- Conditions
- Lung Cancer
- Interventions
- carboplatin, gemcitabine hydrochloride, paclitaxel
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
- Conditions
- Carcinoma, Pancreatic Ductal
- Interventions
- Paclitaxel and gemcitabine
- Drug
- Lead sponsor
- New York Presbyterian Brooklyn Methodist Hospital
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2012
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Lung Cancer, Lymphoma, Pancreatic Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pancreatic Neoplasms, Pancreatic Cancer
- Interventions
- Gemcitabine with escalating ascorbic acid
- Drug
- Lead sponsor
- Joseph J. Cullen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- LMS - Leiomyosarcoma, Uterine Leiomyosarcoma
- Interventions
- Gemcitabine, Dacarbazine, Cytoreductive Surgery, Functional Assessment of Cancer Therapy (FACT) G questionnaire, Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Scan, Gadolinium
- Drug · Procedure · Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer
- Interventions
- imatinib mesylate by mouth, Gemcitabine Intravenous
- Drug
- Lead sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Tacoma, Washington